calcitonin (Fortical Injection / Forcaltonin)

Hydroxyapatite-based aqueous two-phase capillary suspensions for injectable scaffolds.

Kazama Ryotaro R, Ito Hiroki H, Shono Atsushi A

Artificial bone materials are a new therapeutic strategy to overcome the shortage of donors and the risk of complications associated with conventional bone grafting. Injectable materials are being investigated for their potential application in bone tissue regeneration as materials that can be delivered to bone defects using a minimally invasive method. Capillary suspensions are three-phase systems comprising solid particles, a dispersing medium, and a secondary immiscible fluid; they exhibit viscoelastic changes upon the addition of a small amount of secondary fluid. However, because conventional capillary suspensions rely on oils with poor biocompatibility, there are challenges in applying them as biomaterials despite their excellent characteristics. In this study, we introduced an aqueous two-phase system (ATPS) and developed an injectable capillary suspension (hydroxyapatite-polyethylene glycol (PEG)/dextran (DEX)) based on hydroxyapatite particles, which are the main components of bone. Rheological analysis showed that the yield stress of the hydroxyapatite-PEG/DEX capillary suspension varied depending on the amount of DEX-rich phase added. The hydroxyapatite-PEG/DEX capillary suspension exhibited thixotropic behavior, characterized by shear-induced structural breakdown followed by structural recovery, demonstrating superior structural stability compared to a single-fluid suspension. ATPS-based capillary suspensions incorporating hydroxyapatite particles are promising base materials for application as an injectable bone substitute that combines flowability during injection with the ability to maintain its shape after injection.

Correction: Injectable hydrogels with ROS-triggered drug release enable the co-delivery of antibacterial agent and anti-inflammatory nanoparticle for periodontitis treatment.

Zhu Yujing Y, Xiu Ziliang Z, Jiang Xiaoxi X, Zhang Huifang H et al.

Alginate-based long-acting injectable formulations: recent advances, biomedical applications, and translational challenges.

Mukherjee Swarupananda S, Chakraborty Subhasis S, Bhattacharya Joyeeta J, Dutta Koustav K et al.

Currently, numerous short-acting formulations are prescribed to patients to administer various therapeutics, which requires repetition of dosage, that may lead to poor patient compliance. Long-acting injectables are such kind of controlled or sustained-release novel formulation that can be fabricated to deliver the active ingredients into the target area for a prolonged time, lasting days, weeks, or months after administration. Alginate-based long-acting injectable (LAI) formulations are comparatively new in the market. Alginate is a natural polymer and a polysaccharide obtained from brown seaweed and some special bacteria. The biocompatibility and biodegradability play an important role in long-acting injectable formulations. As a result, alginate-based LAIs may offer good biocompatibility and provide prolonged drug release, depending on the formulation design and drug release characteristics. Using the latest technology in LAIs can also control the immediate burst release of the active ingredients so that unwanted effects can be reduced. Relevant articles were taken from Google Scholar, Web of Science, and Scopus, covering studies published between 2000 and 2026. This review will focus on various latest technologies for the preparation of alginate-based LAIs and their mechanistic release profiles, and lastly, the applications and challenges toward the biomedical field will also be discussed.

Sustained intratumoral oligonucleotide delivery via the injectable biomaterial B​ioMATA.

Björgvinsdóttir Unnur J UJ, Marchard Laura O LO, Løvschall Kaja B KB, Melander Fredrik F et al.

Oligonucleotide therapeutics hold great promise for cancer therapy, yet their clinical translation has been limited, partly due to inefficient delivery. To address these challenges, we developed BioMATA, an injectable biomaterial technology designed for localized delivery of oligonucleotide therapeutics with minimal systemic exposure. BioMATA is a free-flowing liquid at injection, compatible with standard thin-needle administration, and forms a semi-solid depot upon injection into tissue. Through controlled diffusion, BioMATA releases oligonucleotides locally in a sustained manner. In this work, we explore the use of BioMATA for the treatment of solid cancers. We demonstrate sustained gene silencing in vitro, and multi-week release with intratumoral retention and limited systemic dissemination in vivo. Intratumoral administration of unformulated CpG oligodeoxynucleotides caused acute body weight loss that was mitigated by BioMATA delivery. BioMATA accommodates structurally distinct oligonucleotide classes and allows two cargoes to be co-formulated in a single depot, establishing it as a versatile platform for localized, sustained oligonucleotide delivery.